宜宾什么叫线雕鼻(宜宾胸部下垂怎么解决) (今日更新中)

BEIJING, July 26 (Xinhuanet) -- Some forms of medical research involving animals containing human material should be more tightly regulated, a report warned.The warning was issued on Friday by an expert working group from the Academy of Medical Sciences in Britain.The report suggested the ban of the use of animal cells that can produce human sperm or egg cells. "We don't want scientists to cause problems for the future by overstepping the mark of what is publicly acceptable," said Professor Robin Lovell-Badge, a member of the expert working group.The controversy partly originated from a medical research in Britain. Three years ago, the researchers produced human embryos with the nucleus hollowed cow eggs, according to the Associated Press."This is a complex research area and there should be an ongoing dialogue between scientists, regulators and the wider public to address emerging issues." said Martin Bobrow, a professor of medical genetics at the University of Cambridge.

SAN FRANCISCO, Sept. 9 (Xinhua) -- AOL's chief executive officer (CEO) Tim Armstrong has reached out to Yahoo for talks of a merger of the two companies, U.S. media reported on Friday.Armstrong is discussing options for a combination aimed at strengthening the two Internet companies, Bloomberg quoted two people who are familiar with the matter as saying.The report said that the AOL CEO had been interested in a merger with Yahoo last year but was rejected while Carol Bartz served as Yahoo CEO, who was ousted by Yahoo's board on Tuesday.Reconsidering the option after Bartz's departure, Armstrong has talked with private equity firms and investment bankers from Allen & Co. working with Yahoo.Under one scenario being considered, Yahoo would acquire AOL and Armstrong would become CEO of the combined company, said the source.Both Yahoo and AOL are suffering from declining revenues, struggling to compete against companies like Google and Facebook. Some analysts said that the merger could not provide a long-term solution to the problems the two companies face after they failed to keep up with Internet trends.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SHENZHEN, June 18 (Xinhua) -- China established its first national gene bank on Friday in south China's city of Shenzhen with the support of the Beijing Genomics Institute (BGI), officials said.With the establishment of the National Gene Bank in Shenzhen, China will be able to better protect, research and utilize its precious genetic resources, boosting the genetics industry and safeguarding the country's genetic information, said Qi Chengyuan, head of the high-tech industry department of the National Development and Reform Committee (NDRC).The gene bank, which was approved by the NDRC in January, is based on data and facilities belonging to the BGI, but will grow with the help of extensive cooperation with other biological organizations both home and abroad, Qi said.The national gene bank "aims to lead the development of international bioindustry as one of the world's largest gene banks," said Yang Huanming, the BGI's president.The BGI, the world's largest genome-mapping institute, has more than 1,000 biological analysis devices working with top-of-the-line genome-sequencing machines.Analysts say the BGI differs from conventional labs, as it can handle data in vast quantities and industrialize its research. Some believe lower wages in China have also contributed to the BGI's competitiveness.Yang Bicheng, the BGI's spokesman, said the payment and welfare packages BGI offers are competitive in China's bioindustry."A researcher with about two years of experience earns around 100,000 yuan (15,440 U.S. dollars) a year. More outstanding researchers can get more, but the gap is not too great," Yang said.Yang said greater motivation comes from better prospects for academic achievements."Our young researchers can work with the world's leading scientists, participate in global science projects and be pioneers in new fields of research. Only BGI offers these kinds of opportunities in China," Yang said.The BGI has published 18 research papers in Science Magazine and the Nature Journal since 2007. The facility has become an international center for genome research and industrialization, with advanced technology and top talent, said Ji Xiaoming, head of the international cooperation department of the Ministry of Science and Technology.China is working to make its genetic research industry into one of the country's pillar industries.A plan approved by the State Council, or China's cabinet, in October 2010 said China will boost the industry by encouraging innovation, promoting industrial application of biological research, fostering market demand and deepening international cooperation.

BEIJING, Aug. 30 (Xinhua) -- China's second moon orbiter, the Chang'e-2, has arrived in outer space about 1.5 million km away from Earth and is now orbiting the second Lagrange Point (L2), where gravity from the sun and Earth balances the orbital motion of a satellite, Chinese scientists said Tuesday.Chang'e-2 entered L2's orbit at 11:27 p.m. last Thursday after spending 77 days traveling away from its previous orbital path around the moon, according to the State Administration of Science, Technology and Industry for National Defence (SASTIND).The SASTIND said that China is now the world's third country or organization to successfully put a spacecraft into orbit around L2, after the European Space Agency (ESA) and the National Aeronautics and Space Administration (NASA) of the United States.The Chang'e-2 orbiter will carry out exploration activities around L2 in the coming year, SASTIND said.There are five so-called "Lagrange Points" about 1.5 million km way from the Earth in the exact opposite direction from the sun. Putting a spacecraft at any of these points allows it to stay in a fixed position relative to the Earth and sun with a minimal amount of energy needed for course correction.The orbiter completed all of its assigned tasks after blasting off on Oct. 1, 2010, according to the SASTIND. Although the orbiter was only supposed to remain in space for six months, the SASTIND decided to assign additional tasks to it, as it still had fuel in its reserve tanks.Traveling into outer space from the moon's orbit was one of the orbiter's most important missions, according to the SASTIND.Before arriving at its current position in outer space, the Chang'e-2 took photos of the northern and southern poles of the moon. It then descended to a lower orbit, approximately 15 km away from the moon's surface, where it captured high-resolution images of the Sinus Iridum, or "Bay of Rainbows," an area where future moon probes may land.The SASTIND is reportedly planning to launch measure and control stations into outer space by the end of the second half of next year. The Chang'e-2 will be used to test the two stations' functionality at that time.China's ambitious three-stage moon mission will include a moon landing, as well as the launch of a moon rover during the second stage, which is scheduled to take place in 2012. During the third phase, another rover will land on the moon and return to Earth with lunar soil and stone samples for scientific research around 2017.China does not currently have a timetable in place for a manned moon landing. It launched its first lunar probe, the Chang'e-1, in October 2007.In 2003, China became the third country after Russia and the United States to send a human into space. Two more manned space missions followed, the most recent of which took place in 2008.0 The Chang'e probes are named after the Chinese legendary goddess of the moon.

来源：资阳报